

CELL THERAPEUTICS INC  
Form 4  
March 26, 2014

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
NUDELMAN PHILLIP M PHD

2. Issuer Name and Ticker or Trading Symbol  
CELL THERAPEUTICS INC  
[CTIC]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction  
(Month/Day/Year)

Director  10% Owner  
 Officer (give title below)  Other (specify below)

3101 WESTERN AVENUE, SUITE 600

03/25/2014

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)

Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

SEATTLE, WA 98121

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount or Price		
Common Stock	03/25/2014		S		2,250 D \$ 3.53	546,369	D
Common Stock	03/25/2014		S		4,950 D \$ 3.535	541,419	D
Common Stock	03/25/2014		S		8,000 D \$ 3.54	533,419	D
Common Stock	03/25/2014		S		2,000 D \$ 3.545	531,419	D
Common Stock	03/25/2014		S		13,097 D \$ 3.55	518,322	D

Edgar Filing: CELL THERAPEUTICS INC - Form 4

Common Stock	03/25/2014	S	6,103	D	\$ 3.555	512,219	D
Common Stock	03/25/2014	S	8,200	D	\$ 3.56	504,019	D
Common Stock	03/25/2014	S	6,900	D	\$ 3.565	497,119	D
Common Stock	03/25/2014	S	200	D	\$ 3.569	496,919	D
Common Stock	03/25/2014	S	20,500	D	\$ 3.57	476,419	D
Common Stock	03/25/2014	S	2,900	D	\$ 3.571	473,519	D
Common Stock	03/25/2014	S	21,900	D	\$ 3.575	451,619	D
Common Stock	03/25/2014	S	1,599	D	\$ 3.58	450,020	D
Common Stock	03/25/2014	S	1,301	D	\$ 3.585	448,719	D
Common Stock	03/25/2014	S	100	D	\$ 3.59	448,619	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned (Instr. 6)
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

